OncoMatch/Clinical Trials/NCT02966756
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Is NCT02966756 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Venetoclax for chronic lymphocytic leukemia (cll).
Treatment: Venetoclax — This is a Phase 2, open-label, multicenter study, evaluating the efficacy of venetoclax in participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) either in presence of 17p deletion (Cohort 1) or those who have failed a B-receptor signaling pathway inhibitor (BCRI) therapy and who have also failed, or were unable to receive chemoimmunotherapy (CIT) irrespective of 17p status (Cohort 2).
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Required: TP53 17p deletion
Allowed: TP53 mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: any prior therapy
relapsed or refractory CLL/SLL after receiving at least one prior line of therapy
Cannot have received: BCL-2 inhibitor (venetoclax)
Participant has previously received venetoclax or other BCL-2 inhibitors
Cannot have received: allogeneic stem cell transplant
Participant has undergone an allogeneic stem cell transplant
Lab requirements
Blood counts
adequate bone marrow function, per laboratory reference range at screening
Kidney function
adequate renal function, per laboratory reference range at screening
Liver function
adequate hepatic function, per laboratory reference range at screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify